3 Nov 2010

MVI is sponsoring one symposium at the conference.

Recent progress and future opportunities in developing malaria vaccines employing heterologous prime-boost strategies

Friday, November 5, 2010
8:00 a.m.–9:45 a.m.
Location: Atlanta Marriott Marquis, Imperial Room A

Vaccines will be an essential tool for preventing morbidity and mortality associated with malaria, and are also expected to have a pivotal role in future elimination and eradication campaigns. A first generation malaria vaccine (RTS,S) is currently the subject of a large multi-center Phase 3 trial in sub-Saharan Africa. Toward the development of next generation vaccines with higher levels of protective efficacy, preclinical and early clinical data strongly support the development of vaccines employing heterologous prime-boost regimens. This symposium will focus on an array of promising prime-boost strategies that are yielding promising preclinical and clinical efficacy data, as well as the development and policy challenges that can be anticipated in implementing these more complex, multi-component vaccines.

Learning objectives

Objective 1: Participants will learn about various malaria prime-boost vaccine strategies currently being evaluated.

Objective 2: Participants will become familiar with the rationale behind the selection of complementing vaccine delivery technologies to elicit maximal humoral and cellular immune responses with good memory function.

Objective 3: Participants will also learn about the unique development and implementation strategies that are anticipated for this more complex type of vaccine approach; namely the use of multiple vaccine components that must be administered in a specific order to ensure optimal effectiveness.


5 minutes

Introduction to session

Ashley Birkett, 
MVI (Moderator)

18 minutes

Virus-based prime-boost strategies for malaria

Adrian Hill, Oxford University

18 minutes

Prime-boost strategies employing plasmid DNA and adenoviruses

Tom Richie, US Military Malaria Program

18 minutes

Adenoviruses and proteins in prime-boost regimens

Jerald Sadoff, 

18 minutes

Programmatic suitability of prime-boost immunization

Vasee Moorthy, 
WHO Initiative for Vaccine Research

5 minutes: after each session

Moderated Q&A session

Moderator, All Faculty


Symposium close